Drug details

Zontivity (vorapaxar tablets)

type of Thrombin Inhibitors, Protease Activated Receptor-1 (PAR-1) Inhibitors

Zontivity (vorapaxar) is a PAR-1 antagonist, or an anti-platelet medication, used for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD).

This drug may have the following side effects:

• carbamazepine,
• rifampin,
• itraconazole,
• ketoconazole,
• posaconazole,
• clarithromycin,
• nefazodone,
• ritonavir,
• saquinavir,
• nelfinavir,
• indinavir,
• boceprevir,
• telaprevir,
• telithromycin,
• conivaptan,
• St. John's wort, and
• phenytoin

The following drugs are related to Zontivity, either as a replacement or used together:

• Calan (verapamil hcl)
• Calan SR (verapamil hydrochloride sustained-release oral caplets)
• Cardizem (diltiazem hydrochloride)
• Cardizem CD (diltiazem hcl)
• Cardizem LA (diltiazem)
• Coreg (carvedilol)
• Coreg CR (carvedilol phosphate extended-release)
• Plavix (clopidogrel bisulfate)
• Coumadin (warfarin sodium)
• Jantoven (warfarin sodium tablets)
• Trandate (labetalol)
• Verelan (verapamil hydrochloride)